Publications by authors named "Gary Hantsbarger"

Claim this Profile
P
Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.
Chitra Karki, Gary Hantsbarger, Erika Turkstra, Elisabetta Fenu, Ken Genenz

BMC Gastroenterol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn's perianal fistulas.
Chitra Karki, Amod Athavale, Vijay Abilash, Gary Hantsbarger, Parnia Geransar

World J Gastrointest Surg· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn's Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases.
Chitra Karki, Dominick Latremouille-Viau, Inmaculada Gilaberte, Gary Hantsbarger, Hela Romdhani

Pharmacoecon Open· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.
Julian Panés, Gerd Bouma, Marc Ferrante, Torsten Kucharzik, Maria Nachury, Gary Hantsbarger

Inflamm Bowel Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
Timothy Card, Ryan Ungaro, Fatima Bhayat, Aimee Blake, Gary Hantsbarger

Aliment Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers.
Gary D Novack, Richard A Lewis, Roger Vogel, Neha Sheth, Dennis Swearingen, Gary Hantsbarger

J Ocul Pharmacol Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Jeffrey S Heier, Andrew N Antoszyk, Peter Reed Pavan, Steven R Leff, Philip J Rosenfeld, Gary Hantsbarger

Ophthalmology· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Philip J Rosenfeld, Jeffrey S Heier, Gary Hantsbarger, Naveed Shams

Ophthalmology· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis